tofacitinib rheum
Selected indexed studies
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Ann Rheum Dis, 2023) [PMID:36357155]
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. (Ann Rheum Dis, 2021) [PMID:33906853]
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. (Ann Rheum Dis, 2021) [PMID:33741556]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023) pubmed
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. (2021) pubmed
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. (2021) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. (2020) pubmed
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. (2023) pubmed
- The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. (2016) pubmed
- JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. (2023) pubmed
- Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. (2023) pubmed
- Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. (2023) pubmed